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INTRODUCTION
Regulatory T cells (Tregs) are immunosuppressive cells that regulate function of the immune system. They are key in maintaining peripheral immune tolerance. Tregs have defined roles in various pathological settings including cancer, autoimmune diseases and transplant rejection, where they contribute to disease progression [1, 2] . Given their role in immune modulation under pathological conditions, Tregs have increasingly been targeted for novel immunotherapies with some promising results in clinical trials [3, 4] . Current approaches include Treg depletion and functional blockade to enhance immune responses or autologous transfer of Tregs to dampen immune responses in certain scenarios [3] [4] [5] .
Tregs are broadly divided into thymic-derived Tregs (tTregs) and peripheral-induced Tregs (pTregs). Both of these Treg subsets were originally defined as expressing the forkhead box P3 transcription factor (FoxP3) and the alpha chain of the IL-2 receptor (CD25). FoxP3 is crucial for development and maintenance of the suppressive Treg lineage [2] . pTregs comprise two further FoxP3 − subsets; IL-10 secreting Type 1 Tregs (Tr1) and T helper 3 Tregs (Th3) [6, 7] . Recent years have seen significant efforts into characterizing Treg markers for effective identification and isolation of Treg subsets [2, 5] . The expression of FoxP3, CD25 or the 'immune checkpoint' molecules proposed to identify Tregs, can also define non-regulatory T cells (Tconv) and effector T cells (Teff) [5, 8] . CD25 is a well-recognized T cell activation marker. The immune checkpoint molecules, CTLA-4, PD-1, LAG-3 and TIM-3, can also be up-regulated on activated Tconv and Teff [5] . Neuropilin 1 (NRP1), a promising Treg surface marker, is also up-regulated during inflammation in vivo [9, 10] . FoxP3 can be transiently expressed in T cells undergoing activation or in inflammatory microenvironments [11, 12] .
We have recently reviewed current Treg markers [5] . Of particular interest are two molecules involved in the expression and activation of transforming growth factor-beta (TGF-β) that selectively identify activated Tregs: glycoprotein A repetitions predominant (GARP/ LRRC32) and latency-associated peptide (LAP). LAP and TGF-β form inactive complexes on the surfaces of T cells, known as latent TGF-β complexes. These complexes can be cleaved to release active TGF-β. GARP plays a critical role in the formation and expression of latent TGF-β complexes at the cell surface by anchoring the complexes to the cell membrane [13, 14] .
GARP is a transmembrane protein that has been identified on activated Tregs, megakaryocytes and platelets [13, 15, 16] . GARP forms a positive-feedback loop with FoxP3 where expression of one enhances expression of the other [16, 17] . Retroviral expression of GARP on human T helper (Th) cells with TCR stimulation results in stable re-programming of Th cells into functionally suppressive FoxP3-expressing Tregs [16, 18] . Down-regulation or silencing of GARP on FoxP3 + Tregs decreases both FoxP3 expression and suppressive activity [16, 18] . Induction of GARP on naïve human T cells also induced partial Treg functionality in vitro [19] . GARP itself might contribute directly to immune suppression as shown in a humanized mouse model where treatment with soluble GARP (sGARP) prevented lethal graft-versus-host disease (GVHD) following xenogeneic tissue transplantation [20] . sGARP also induced development of naïve CD4 + human T cells into Tregs in vitro [20] .
LAP is up-regulated on activated Tregs and has been characterized on megakaryocytes and immature dendritic cells (DCs) [21] . LAP has been utilized in conjunction with the IL-1 receptors Type I/II (CD121a/b) for identification and isolation of functional FoxP3 + human Tregs [22] . Highly suppressive FoxP3 − LAP + Tregs have also been identified in humans [23] . LAP was recently used to effectively identify and isolate functional Tregs from patients following immunotherapy with anti-CTLA-4 antibody [24] .
Another marker that has been the focus of significant research is the Ikaros zinc finger transcription factor, Helios. It was first identified as a selective tTreg marker in mice [25] . However, in humans, Helios has been characterized in pTregs, tTregs, CD8 + T cells, activated T cells and T cells in inflammatory microenvironments [5, 26] . Helios has been implicated in Treg development and stability by repressing the IL-2 gene promoter [27, 28] . Helios + Tregs have been shown to exhibit superior suppressive activity, compared to Helios − Tregs in mice [29] . In human Tregs, Helios has been reported to enhance FoxP3 expression by binding the FoxP3 promoter [30] . Helios knockdown impaired the suppressive activity and down regulated FoxP3 expression [30] . While the exact role of Helios is uncertain, it is acceptable that Helios defines a highly suppressive Treg subset with distinct phenotypic and functional features [31] [32] [33] . FoxP3 + Helios + Tregs are significantly expanded in circulation and tumor microenvironment in various cancers including colorectal cancer, renal cell carcinoma and glioblastoma [34] [35] [36] [37] .
The Figure 1A ). This is consistent with a recent observation in patients with acute coronary syndrome [38] . 
CD4 + T cells expressing GARP/LAP make IL-10 but not IFN-γ
We then investigated the nature of cytokines released from different subpopulations expressing or lacking GARP/LAP. PBMCs were stimulated by anti-CD3/28 for 18-20 hours to allow induction of GARP/ LAP. We noticed GARP/LAP could not be induced 
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+/− T-cell subsets, we investigated their ability to proliferate in response to TCR stimulation. We set up crude proliferation assays in which all cell populations in PBMCs were kept. This allows the release of IL-2 from TCR-stimulated CD4 + T effector cells that can be used by cells expressing the high affinity IL-2R α chain (CD25). We found that FoxP3 + Helios − CD4 + Tregs proliferated significantly higher (59.2 ± 5.4%, Figure 5A & 5B) than all other subpopulations, which showed similar proliferation levels (32-35%, Figure 5B ). Having less proliferation capability in response to TCR stimulation even in the presence of IL-2 secreted by effector cells confirms that FoxP3 + Helios + are more anergic, a characteristic of bona fide Tregs. We measured levels of CD25 expression before and after TCR stimulation to determine the role of IL-2 in inducing proliferation Figure 5D ), but not on FoxP3 + Helios + Tregs, which showed similar levels of CD25 as per before stimulation (79.7 ± 8.5%, Figure 5D) levels of IL-10 + cells (6.4 ± 2.1%, Figure 4E ), and did not secrete significant levels of effector cytokines. [32] . Very recently, in a Helios reporter mice, it was shown that Helios + Tregs have superior ability than Helios − Tregs to suppress T-cell proliferation and cytokine production [29] . Our findings suggest that Helios defines a more suppressive Treg subset. This must however be confirmed in further mechanistic assays. As suggested earlier, FoxP3 + Helios − Tregs might simply contain a mixture of non-suppressive and suppressive T cells rather than being intrinsically less suppressive than FoxP3 + Helios + Tregs. Indeed, human Helios + and Helios − Tregs have previously been reported to exhibit a similar suppressive capacity although Helios − secreted greater levels of IFN-γ [32] . The different rates of proliferation reported in our study must also be interpreted carefully; although Tregs show an anergic phenotype in vitro, they proliferate at a much higher rate in vivo [43] .
The FoxP3 − Helios + T cell population did not secrete significant levels of IL-10, IL-2 or IFN-γ and showed a proliferative capacity comparable to that of FoxP3 + Helios + Tregs. We can speculate that these might be TGF-β-dependent Th3 cells. Expression of GARP and LAP, as surrogate markers for TGF-β, on these non-cytokine secreting T cells could further support the case for Th3 cells being present. Helios has also been reported to be up-regulated in Th2 and follicular T helper cells (Tfh) independently of FoxP3 [44] . Further studies investigating the cytokine secretion profile of GARP/LAP expressing T cells with FoxP3 and Helios are required.
In accordance with other reports identifying GARP (Figure 2A & 2B) . In contrast, FoxP3 + Helios + cells mainly increased GARP expression with LAP increased to a lower extent (Figure 2A ). This could indicate that FoxP3 inhibits LAP expression or perhaps that, following activation, FoxP3 + Helios + Tregs release TGF-β from the cell surface. Indeed Tregs utilize TGF-β as a suppressive mechanism. One recent murine study reported that GARP expression was induced on FoxP3 + T cells following 24 hours of in vitro activation, while LAP expression was only induced after 48-72 h of activation [45] . A FoxP3 − LAP + Treg subset was also identified in humans [23] . These LAP + Tregs secreted IL-10, IFN-γ and TGF-β upon activation but were not studied for expression of GARP and Helios [23] .
When interpreting these results, we should take into account the significant functional and phenotypic heterogeneity and plasticity that Tregs exhibit [12, 46, 47] . Numerous tissue-and antigen-specific Treg subsets with distinct features exist, including follicular Tregs, 'ex-Tregs', and IL-17-secreting Tregs. Immune regulation involves complex interplay and cross-talk between Treg subsets, Teff, DCs and other immune cells. Identification of highly suppressive individual Treg subsets is important. However, these subsets should be considered in the overall context of physiological or pathological immune functioning. Impact of Treg subsets on clinical outcomes can vary considerably [5, 48] . For example, immunotherapies enhanced Helios expression in CD4 + Tregs in the responder group of rheumatoid arthritis patients [49] . In contrast, in SLE patients, levels of Helios + Tregs were significantly increased and correlated positively with SLE disease activity [41, 42] .
Therapeutic modalities for treating autoimmune diseases, allergies and graft rejection should be designed to induce and/or expand the most suppressive Treg subsets. Our work suggests these might be the FoxP3 
MATERIALS AND METHODS
Cell isolation and preparation
Whole blood samples were either collected from healthy donors or were obtained from UK National Blood Service. Ethical approvals were obtained prior to samples' collection. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Hypaque (Sigma-Aldrich, UK) density gradient centrifugation. PBMCs were then frozen at 5-10 × 10 6 cells/ml in cryovials in 1 ml of freezing media (50% FCS, 40% RPMI-1640 and 10% DMSO) and stored in liquid nitrogen (LN) for later use. Trypan blue was used for PBMC viability testing and counting.
GARP and LAP expression on Treg subpopulations
PBMCs were thawed and suspended at 2 × 10 6 cells/ well in 2 ml complete medium [RPMI-1640 supplemented with L-glutamine 2 mM, 10% FCS, Streptomycin 100 μg/ ml and Penicillin 100 Units/ml] in a 24-well non-treated culture plate. PBMCs were either plated as non-activated in non-coated wells or activated in pre-coated wells with plate-bound 2 μg/ml anti-CD3 antibody (clone OKT3 clone, eBioscience, Hatfield, UK) and 2 μg/ml anti-CD28 antibody (CD28.2 clone, eBioscience). Plated cells were incubated for 18-20 hours in a humidified incubator at 37°C 5% CO2. Cells were collected and blocked for FcR with IgG from human serum (Sigma-Aldrich, UK) and were then stained for extracellular markers using mouse anti-human CD4-PerCP-Cy5.5 (eBioscience), mouse anti-human CD3-APC-H7 (BD Biosciences, Oxford, UK), mouse anti-human GARP-APC (BD Biosciences), and mouse anti-human LAP-PE (BD Biosciences). For intracellular markers, cells were subsequently fixed, permeabilized and blocked using rat serum (eBiosceince) and mouse serum (Sigma-Aldrich) before staining with rat anti-human FoxP3-PE-Cy7 (PCH101 clone, eBioscience) and Armenian hamster anti-mouse/human Helios-FITC (22F6 clone, Biolegend, Cambridge, UK). Following two further permeabilization washes, cells were re-suspended in flow cytometry buffer. Fixation, permeabilization and flow cytometry buffers were all from eBioscience or BD Biosciences and prepared as per the manufacturer's instructions. Flow cytometric data was acquired on a FACSVerse or FACSCanto II flow cytometers (BD Biosciences, USA). Data analysis was performed using BD FACSuite or FlowJo version x 10.0.7r2 software.
Cytokine release from different Treg subpopulations
Thawed PBMCs were plated in complete medium in a 24-well non-treated culture plate pre-coated with 2 μg/ ml anti-CD3 and 2 μg/ml anti-CD28. To investigate IFN-γ and IL-10 release from subpopulations expressing GARP/ LAP or not, cells were incubated for 24 hours at 37°C 5% CO2 and 1 μg/ml Golgi Plug (BD Biosciences) was added for the last 4 hours of activation. Cells were first stained for extracellular markers using mouse anti-human CD4-PerCP-Cy5.5, mouse anti-human CD3-APC-H7, mouse anti-human GARP-APC, and mouse anti-human LAP-PE. For intracellular cytokines, cells were subsequently fixed, permeabilized and blocked using mouse serum before staining with anti-human IL-10-FITC (eBioscience) and mouse anti-human IFNγ-PE-Cy7 (BD Pharmingen, BD Biosciences, UK).
In another experimental panel to investigate IFN-γ and IL-10 release from different subpopulations expressing FoxP3/Helios or not, cells were activated for 24 hours, with Golgi Plug added for the last 4 hours, then stained for extracellular markers using mouse antihuman CD4-PerCP-Cy5.5 and mouse anti-human CD3-APC-H7. For intracellular transcription factors/cytokines, cells were subsequently fixed, permeabilized and blocked using rat and mouse serum before staining with rat antihuman FoxP3-PE (eBioscience) and Armenian hamster anti-mouse/human Helios-FITC, together with rat antihuman IL-10-APC (BD Pharmingen) and mouse antihuman IFNγ-PE-Cy7. To investigate IL-2 release, cells were activated for 6 hours, with Golgi Plug added for the last 4 hours, followed by staining with rat anti-human IL-2-PE-Cy7 (eBioscience) and flow cytometric and data analysis were performed as described above.
CFSE-based proliferation assays
Proliferation of different subsets was measured by carboxyfluorescein diacetate succinimidyl ester (CFSE)-based proliferation assays. Briefly, PBMCs were suspended at 1 × 10 6 cells/ml in pre-warmed 0.1% BSA in PBS and incubated with 0.25 μM CFSE/ml (eBioscience) for 10 minutes at 37°C, followed by a series of washes. CFSE-labeled cells were suspended in complete medium and were polyclonally stimulated with plate-bound 2 μg/ml anti-CD3 and 2 μg/ml anti-CD28. Cells were incubated for 3 days in a humidified incubator at 37°C 5% CO 2 . CFSE-labeled cells were then stained for surface markers using anti-CD3-APC-H7 and anti-CD4-PerCp-5.5 antibodies, followed by intracellular staining using antiFoxP3-PE-Cy7 and anti-Helios-APC antibodies. In another experimental setting, CD25 expression in different FoxP3/Helios CD4 + T-cell subsets was determined using mouse anti-human CD25-APC-H7 (BD Biosciences). Proliferation and various marker expressions in different subsets were evaluated by flow cytometry.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, United States). Paired T test was used to test for differences within groups. www.impactjournals.com/oncotarget P value ≤ 0.05 was considered statistically significant. The data are presented as means ± SEM.
